Head-to-head · Value Score
CoreAge Rx vs TelePeptide
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, TelePeptide a 71. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-nameTelePeptide
#232 · Grade C · Watch List
Est. first month
From $169/mo (starting dose, medication billed separately, compounded)
Save ~87% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 71 — an est. $149/mo first month, with no teaser step-up baked in. TelePeptide isn't out of it: Shoppers who want all-in compounded GLP-1 (sema/tirz, injectable + oral) from $169/mo; LegitScript-certified, 48 states.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | TelePeptide |
|---|---|---|
| Value Score | 93 (A+) | 71 (C) |
| Est. first month | $149/mo | From $169/mo (starting dose, medication billed separately, compounded) |
| Save vs brand-name | ~89% | ~87% |
| Semaglutide | $149/mo | From $169/mo (starting dose, medication billed separately, compounded) |
| Tirzepatide | $349/mo | From $214/mo (starting dose, medication billed separately, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
TelePeptide
TelePeptide is a LegitScript-certified US direct-pay telehealth practice offering physician-supervised compounded GLP-1 therapy — semaglutide and tirzepatide — in injectable and oral dissolvable tablet…
Why it's a deal
- LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
- All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
- Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
- 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
- 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime
The fine print
- Compounded medications are not FDA-approved; no pharmacy partner named publicly
- Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
- Labs not included in any plan
- Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
- Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to TelePeptide.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.